Cizzle Bio announced Dr. Ron Greeno as its new Chief Medical Officer

About Cizzle Bio

Cizzle Bio, Inc. stands at the forefront of biotechnological innovation, dedicated to revolutionizing the detection of lung cancer through groundbreaking diagnostic tools. With exclusive rights to detect the CIZ1B Biomarker in the USA and Canada, we are driven by a commitment to improve early cancer detection and enhance patient outcomes.

About Dr. Ron Greeno

Dr. Greeno has had a remarkable career, starting with founding Cogent Healthcare, where he served as Executive Vice President for Strategy and Chief Medical Officer until it merged with Sound Physicians. He then took on leadership roles at IPC and TeamHealth, helping to shape hospitalist medicine and physician management across the country. As a board-certified physician in internal medicine, pulmonary medicine, and critical care, Dr. Greeno has spent his career working to improve patient care, advance healthcare policy, and make healthcare delivery more effective. In addition to his clinical leadership, Dr. Greeno has played an important role in healthcare policy and government relations: He served as Senior Advisor for Government Relations at the Society of Hospital Medicine (SHM). He was the former President of SHM, representing 50,000 hospitalist physicians across the country. He has worked closely with Capitol Hill, Medicare, and the Center for Medicare and Medicaid Innovation (CMMI). His work has focused on innovative healthcare payment models aimed at improving care quality and reducing costs. In 2003, he received the SHM Award for Outstanding Service in Hospital Medicine. SHM has also awarded him a Master in Hospital Medicine, making Dr. Greeno one of only a handful of individuals to ever receive this distinction. Three times Modern Healthcare has named Dr. Greeno to its list of the “50 Most Influential Physician Executives,” the first hospitalist physician ever to make this prestigious list. Dr. Greeno’s expertise in value-based care and alternative payment models aligns perfectly with Cizzle Bio’s goal of improving early cancer detection and expanding access to advanced diagnostics.

Qualifications

• Seasoned physician executive and healthcare innovator with 30 years of experience
• Expertise in clinical strategy, policy development, and healthcare payment innovation
• Deep expertise in value-based care and alternative payment models

Responsibilities

• Advance biomarker-driven diagnostics for early cancer detection
• Navigate reimbursement and healthcare payment models to improve accessibility
• Expand partnerships with hospitals, payers, and regulatory bodies to promote the adoption of Cizzle Bio’s technologies